BridgeBio Oncology Therapeutics (BBOT) Share-based Compensation (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Share-based Compensation for 3 years, with the latest figure at $61.5 million in Q1 2026.

• Quarterly Share-based Compensation rose 9708.61% year-over-year to $61.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.5 million (up 1449.9% YoY) and the FY2025 annual result came in at $41.2 million, up 1695.99% from the prior year.
• Share-based Compensation rose to $61.5 million in Q1 2026 per BBOT's latest filing, from $1.4 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $61.5 million in Q1 2026 and troughed at $279000.0 in Q2 2024.
• A 3-year average of $8.6 million and a median of $821500.0 in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation retreated 5.0% in 2025, then jumped 9708.61% in 2026.
• Over 3 years, Share-based Compensation stood at $2.3 million in 2024, then slumped by 37.88% to $1.4 million in 2025, then jumped by 4215.79% to $61.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $61.5 million, $1.4 million, and $875000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.